Development of a novel cancer therapy combining DNA damage response inhibitors and radiotherapy
| Project/Area Number |
26461881
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
Hosoya Noriko 東京大学, 大学院医学系研究科(医学部), 講師 (00396748)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | DNA損傷応答 / 放射線抵抗性 / がん |
|---|
| Outline of Final Research Achievements |
In order to develop effective cancer therapies targeting DNA damage response, it is important to clarify the molecular mechanisms which induce abnormalities in DNA damage response in each cancer. In this study, we investigated the mitotic roles of the synaptonemal complex protein SYCE2, which is not expressed in normal mitotic cells but aberrantly expressed in cancer. We found that SYCE2 activates the ATM-mediated DNA damage response and induces radioresistance and that treatment with the ATM inhibitor abrogates radioresistance observed in SYCE2-expressing cells.
|
Report
(4 results)
Research Products
(24 results)
-
-
-
-
-
-
-
-
-
-
-
[Presentation] 医学教育の現状2016
Author(s)
細谷紀子、宮川清
Organizer
日本放射線影響学会第59回大会
Place of Presentation
JMSアステールプラザ（広島県広島市）
Related Report
Invited
-
-
-
-
-
-
-
-
[Presentation] 腫瘍血管の新生を阻害する2015
Author(s)
細谷紀子
Organizer
第74回日本医学放射線学会総会
Place of Presentation
パシフィコ横浜（神奈川県横浜市）
Year and Date
2015-04-18
Related Report
Invited
-
-
-
-
-
